Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALSYMPCA trial of radium-223 in hormone refractory prostate cancer with bone metastases
ACTRN12609000262202Phase 3Active, not recruiting
- Sponsor
- Algeta ASA
- Start
- Jun 2008
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in castration-resistant prostate cancer (CRPC) comparing Radium-223 dichloride + best standard of care with Placebo + best standard of care (2 arms). Primary endpoint: Overall survival. Started Jun 2008; status: active, not recruiting.
02
Drugs
radium-223 dichloride
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on ACTRN12609000262202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000262202.